Newly Diagnosed With IBD? Your First 90 Days, Step by Step

Newly Diagnosed With IBD? Your First 90 Days, Step by Step

Being told you have inflammatory bowel disease (IBD) can feel overwhelming. The first few months after diagnosis are often the most intense, with new medications, symptoms to track, and much information to absorb. Understanding what to focus on in these early weeks can make a significant difference to your confidence, symptom control, and long-term outcomes.

What happens in the first 90 days

The period immediately after diagnosis focuses on three key goals: reducing active inflammation, stabilising symptoms, and building a sustainable management plan. Your gastroenterology team will usually start or adjust medication to bring inflammation under control as quickly as possible. This often involves corticosteroids for rapid symptom relief, alongside longer-term treatments such as immunosuppressants or biologic therapies that target the underlying immune dysfunction.

You may also undergo further investigations to clarify disease extent and severity. This might include additional blood tests, faecal calprotectin monitoring (a stool test reflecting gut inflammation), and sometimes repeat imaging or endoscopy to assess treatment response.

Understanding your diagnosis

IBD is an umbrella term for conditions causing chronic inflammation in the digestive tract. The two main types are Crohn’s disease, which can affect any part of the gut from mouth to anus, and ulcerative colitis, which is limited to the colon and rectum. Both are immune-mediated conditions where the body’s immune system mistakenly attacks the gut lining, causing inflammation, ulceration, and symptoms including diarrhoea, abdominal pain, fatigue, and weight loss.

Your consultant should explain your diagnosis in detail, including disease location, behaviour, and any complications identified during diagnostic tests. This information shapes your treatment plan.

Starting treatment

Most people begin treatment soon after diagnosis. Medication choice depends on disease severity, location, and individual factors.

Corticosteroids

Steroids such as prednisolone are often used to quickly reduce inflammation during a flare. They are effective but not suitable for long-term use due to side effects including weight gain, mood changes, and bone thinning. The goal is to taper off steroids as other medications take effect.

Immunosuppressants

Drugs such as azathioprine, mercaptopurine, or methotrexate dampen the immune response driving inflammation. They take several weeks to become fully effective, so are usually started alongside steroids. Regular blood tests monitor for side effects.

Biologic therapies

Biologics are targeted treatments blocking specific proteins involved in inflammation, such as tumour necrosis factor (TNF) or integrins. They are typically used in moderate to severe disease or when other treatments have failed. Examples include infliximab, adalimumab, and vedolizumab.

Tracking symptoms and inflammation

One important skill to develop early is distinguishing between symptoms and inflammation. Not all symptoms reflect active disease. Stress, dietary triggers, or functional gut issues can cause discomfort even when inflammation is well controlled. Conversely, inflammation can sometimes be present without obvious symptoms.

Faecal calprotectin testing monitors gut inflammation without endoscopy. Your team may check this regularly in the first few months to assess treatment response. Blood tests for inflammatory markers such as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) may also be used, though they are less specific.

Keeping a simple symptom diary helps you and your team spot patterns. Note bowel movement frequency and consistency, pain, urgency, blood, and any influencing factors.

Diet in the early weeks

There is no single diet that works for everyone with IBD, and food is not a substitute for medication. However, what you eat can influence symptoms, nutritional status, and gut microbiome composition.

In the first 90 days, the priority is maintaining adequate nutrition and avoiding foods that worsen symptoms. During a flare, many find a lower fibre or low residue diet easier to tolerate. This typically means limiting raw vegetables, whole grains, nuts, seeds, and tough fibres, and choosing well-cooked, softer foods.

If you struggle to eat enough or have lost weight, a dietitian with IBD experience can help tailor a plan meeting your needs. Some people benefit from oral nutritional supplements or, in severe cases, exclusive enteral nutrition (a liquid diet providing complete nutrition that can reduce inflammation in Crohn’s disease).

Building your support network

The early weeks are the time to identify who will support you. This includes your healthcare team, family, friends, and potentially other people living with IBD. Many hospitals have IBD nurse specialists who provide education, coordinate care, and act as a point of contact between appointments.

Patient organisations such as Crohn’s and Colitis UK offer reliable information, local support groups, and online forums where you can connect with others who understand your experience. Being informed and supported reduces anxiety and helps you feel more in control.

What to avoid

During the first 90 days, be cautious about making too many changes at once. Avoid unproven or restrictive diets without professional guidance, as they may worsen nutritional deficiencies. Do not stop or alter prescribed medication without discussing it with your consultant, even if you feel better, as inflammation can persist beneath the surface.

Smoking is particularly harmful in Crohn’s disease and increases the risk of flares, complications, and surgery. If you smoke, stopping is one of the most effective things you can do to improve outcomes. Your GP or IBD team can provide support.

Looking beyond the first three months

By the end of 90 days, many people will have experienced significant improvement. Treatment plans will stabilise, and the focus will shift toward maintaining remission and monitoring for complications. This is also the time to think about longer-term strategies such as optimising nutrition, managing stress, staying physically active, and understanding when to seek help if symptoms return.

IBD is a lifelong condition, but with effective treatment and support, most people can achieve and maintain remission.

Practical takeaways

  • Start medication as prescribed and attend all monitoring appointments.
  • Keep a simple symptom diary to help track patterns and treatment response.
  • Ask for a referral to a dietitian if you are struggling with eating or weight loss.
  • Faecal calprotectin and blood tests help assess inflammation, not just symptoms.
  • Connect with an IBD nurse specialist if your hospital offers this service.
  • Avoid smoking, especially if you have Crohn’s disease.

Conclusion

The first 90 days after an IBD diagnosis are intense, but they are also a time when effective treatment can make a real difference. Focus on understanding your condition, starting medication, tracking inflammation, and building a support network. Symptoms do not always reflect disease activity, so regular monitoring is essential. With the right treatment and support, most people can achieve remission and regain stability over time.

References

  1. Kalla R, Ventham NT, Satsangi J, Arnott ID. Crohn’s disease. BMJ. 2014;349:g6670. doi:10.1136/bmj.g6670
  1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. doi:10.1016/S0140-6736(16)32126-2
  1. Panes J, Vermeire S. Diagnosis and management of ulcerative colitis and Crohn’s disease. BMJ Best Practice. 2020.
  1. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649-670. doi:10.1093/ecco-jcc/jjx008
  1. Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25. doi:10.1093/ecco-jcc/jjw168
  1. Lomer MC. Dietary and nutritional considerations for inflammatory bowel disease. Proc Nutr Soc. 2011;70(3):329-335. doi:10.1017/S0029665111000097
  1. Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018;4(4):CD000542. doi:10.1002/14651858.CD000542.pub3
  1. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120(5):1093-1099. doi:10.1053/gast.2001.23231

This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.

About the Author

Team Vance

Team Vance is the editorial team at Vance Medical, the medical foods company behind this hub. Vance Medical has spent more than thirty years in gastrointestinal medicine, developing nutritional products under the same regulatory frameworks that govern prescription medicines. The Hub exists to make that ground accessible, to people living with Crohn's disease, ulcerative colitis, IBS and related conditions, and to the clinicians treating them. Articles are written and edited in-house, and clinical claims are referenced to published research, with each study linked to its DOI so you can read the source rather than take our word for it. We publish primarily for a UK audience. Nothing here replaces advice from your own GP, gastroenterologist or dietitian.

For general information only. This article is for general information and is not a substitute for professional medical advice, diagnosis or treatment. It reflects the best available evidence at the time of writing and may not capture the most recent developments. Always talk to your GP, pharmacist or healthcare team before acting on anything you read here, and never disregard professional advice or delay seeking it because of something on this site. Where we mention products from Vance Medical Foods Ltd we identify this clearly.
Last updated 4 August 2026
×
×